Browse by author
Lookup NU author(s): Dr Sanjeet Pakrasi,
Professor Alan ThomasORCiD,
Dr Urs Mosimann,
Dr David Cousins,
Professor David Burn,
Professor John O'Brien,
Professor Ian McKeith
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Introduction There is little data on stopping cholinesterase inhibitors in Dementia with Lewy bodies (DLB). Equally, it is not known if increasing the dose of cholinesterase inhibitors may help neuropsychiatric symptoms in advanced DLB. Method We conducted an open label trial with donepezil involving 16 patients with LBD when the dose was reduced and treatment stopped over 4 weeks. Another 7 patients were given a trial of an increased dose of donepezil (15 mg) to resolve reemergent neuropsychiatric symptoms. Results The slow discontinuation protocol was well tolerated in advanced DLB. Five of the seven patients given a trial of a higher dose of donepezil were rated as clinically improved after 12 weeks treatment. Conclusion Cholinesterase inhibitors can be discontinued slowly in advanced DLB. Increasing the dose of donepezil may be of benefit to some patients with DLB who experience a recurrence in their neuropsychiatric symptoms. Copyright (c) 2006 John Wiley & Sons, Ltd.
Author(s): Pakrasi S, Thomas A, Mosimann UP, Cousins DA, Lett D, Burn DJ, O'Brien JT, McKeith IG
Publication type: Article
Publication status: Published
Journal: International Journal of Geriatric Psychiatry
ISSN (print): 0885-6230
ISSN (electronic): 1099-1166
Publisher: John Wiley & Sons Ltd.
Altmetrics provided by Altmetric